39:{"drug_id":924056,"title":"Valsartan","ind":"FDA-Labeled Indications

Heart failure
Hypertension
Myocardial infarction

Non-FDA Labeled Indications

Diabetic nephropathy
Erectile dysfunction
Hypertension - Renal impairment
Impaired cognition
Left ventricular hypertrophy
Restenotic lesion of coronary artery; Prophylaxis
Systolic hypertension, Isolated
Type 2 diabetes mellitus; Prophylaxis

","adult":"

Heart failure
- initial, 40 mg ORALLY twice daily
- maintenance, 80 to 160 mg ORALLY twice daily as tolerated; MAX 320 mg daily
Hypertension
- initial, 80 to 160 mg ORALLY once daily
- maintenance, 80 to 320 mg ORALLY once daily
Myocardial infarction
- as early as 12 hours post-myocardial infarction; initial, 20 mg ORALLY twice daily; may be increased within 7 days to 40 mg twice daily; titrate to 160 mg twice a day as tolerated

","ped":"

General Dosage Information
- safety and efficacy not established in pediatric patients
Hypertension
- initial (6 to 16 years old), 1.3 mg/kg ORALLY once daily; MAX 40 mg/day
- maintenance (6 to 16 years old), up to 2.7 mg/kg ORALLY once daily; MAX 160 mg/day
- may use oral suspension; when the suspension is replaced by a tablet, an increase in the dose may be warranted since the exposure to valsartan in suspension form is 1.6 times greater than the tablet form

","side":"Common

Cardiovascular:Hypotension (5.5% to 6.9%)
Neurologic:Dizziness (2% to 17%), Headache (greater than 1%)
Renal:Serum blood urea nitrogen raised (heart failure, 16.6%), Serum creatinine raised (hypertension, 0.8%; heart failure, 3.9%; post-myocardial infarction, 4.2%)
Respiratory:Cough

Serious

Renal:Acute renal failure
Other:Angioedema, Face, lips, throat

","prgnancy":"D (FDA)
","intermajer":"

Benazepril (established)
Captopril (established)
Enalapril (established)
Enalaprilat (established)
Fosinopril (established)
Lisinopril (established)
Lithium (probable)
Moexipril (established)
Perindopril (established)
Quinapril (established)
Ramipril (established)
Simeprevir (theoretical)
Trandolapril (established)
Trimethoprim (theoretical)

","clinical":"

Patient should avoid activities requiring coordination until drug effects are realized, as this medicine may cause dizziness.
Drug may cause abdominal pain, diarrhea, hypotension, headache, cough, or fatigue.
Advise patient to avoid potassium supplements and foods/salt substitutes that are high in potassium.

","admin":"Oral

take with or without food
shake suspension for at least 10 seconds before dispensing
prepare 4 mg/mL suspension by adding 80 mL of Ora-Plus(R) vehicle to 8 valsartan 80 mg tablets in an amber glass bottle and shake for at least 2 minutes
let stand 1 hour and then shake for at least 1 minute
add additional 80 mL Ora-Sweet(R) vehicle and shake for at least 10 seconds to disperse the content

","interminor":null,"contra":"

Aliskiren (probable)","clas":"Angiotensin II Receptor Antagonist","mode":"Systemic: Valsartan is a nonpeptide angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT 1 receptors in tissues such as vascular smooth muscle and the adrenal gland . In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II . Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium . Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle . Valsartan, by blocking the binding of angiotensin II to the AT 1 receptors, promotes vasodilation and decreases the effects of aldosterone . The negative feedback regulation of angiotensin II on renin secretion also is inhibited, resulting in a rise in plasma renin concentrations and a consequent rise in angiotensin II plasma concentrations; however, these effects do not counteract the blood pressure-lowering effect that occurs .
"}

Arbiten 160 (Valsartan - Tablet 160 mg) – Full Drug Info.

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS